This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Finance & Accounting for Bioscience Companies East
Delivered as a Hybrid Event
September 19-20, 2022Boston, MA

Charles Higgins, CFA
Director at Centri Business Consulting, LLC


Charles is a Director in Centri’s valuation practice with more than 25 years of experience providing a variety of valuation and opinion services for clients, both nationally and internationally.  His skillset spans across a wide variety of industries, including technology, life sciences, healthcare, manufacturing, retail, professional services, and alternative energy.

He has provided fairness and solvency opinions in connection with going private transactions, spin-offs, related-party transactions, recapitalizations, and restructurings.  In addition, Charles has conducted valuations for financial reporting purposes under ASC 820, ASC 805, ASC 350, ASC 360, ASC 718, and ASC 842. He is also experienced in valuing a wide range of complex derivatives, including options, warrants, restricted stock units, performance-based shares, convertible debt instruments and other fixed income securities. Charles also has expertise in performing valuations for IRC 409A and estate and gift tax planning.

Prior to joining Centri, Charles was a Director with CBIZ Valuation Group, LLC.

Charles is a CFA® charter holder and is a member of the CFA Society Philadelphia, the Philadelphia Estate Planning Council, BioNJ, and the Philadelphia Alliance for Capital and Technologies.

Charles has a Master of Business Administration with concentrations in Finance and Information Management from the University of Texas at Austin McCombs School of Business and a Bachelor of Science in Finance from Rider University.

Charles Higgins, CFA's Network

Agenda Sessions

  • Forecasting, Modeling and Valuation Strategies for Life Science Companies